Silly question: now that we have ph1 complete for MND. Assuming no alteration to formulation of MPL or dosage, could we jump straight to Ph2 for other conditions?
Or do we still need to determine safety specifically for people with a particular condition? Would it depend on the condition per regulatory board adjudication?
Silly question: now that we have ph1 complete for MND. Assuming...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.020(9.09%) |
Mkt cap ! $95.01M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 24.5¢ | 22.0¢ | $254.9K | 1.085M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10127 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 200825 | 6 |
View Market Depth
| Last trade - 16.10pm 11/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.020 ( 9.30 %) |
||||
| Open | High | Low | Volume | ||
| 21.5¢ | 24.5¢ | 21.5¢ | 724342 | ||
| Last updated 15.59pm 11/06/2024 ? | |||||
| PAA (ASX) Chart |